The drug price of 'Jakabi' which is used in the treatment of myelofibrosis will be lowered about 40%
The drug price of 'Jakabi (ingredient ruxolitinib)' which is used in the treatment of a rare disease, myelofibrosis, will be lowered about 40%.
According to industry sources, on May 30, Novartis Korea submitted economic evaluation result of Jakabi with the content of reducing the price about 40%...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
